Listen on the go
  • Listen on the Go
    • Faculty & Disclosures
    Dr David Sallman

    H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

    David Sallman, MD, is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, and assistant professor in the Department of Oncologic Sciences at the University of South Florida in Tampa, FL, USA. read more

    Dr Sallman’s interests are myelodysplastic neoplasms (MDS) and acute myeloid leukaemia (AML). His research focuses on the development of targeted therapeutic strategies for patients with MDS and AML, based on the underlying mutational drivers of each disease. Specifically, he studies the genetic drivers of myeloid diseases to improve prognostication for patients and to allow for more personalized treatment.

    He has been the lead principal investigator for phase I, II and III trials in patients with TP53 mutant MDS and AML. Dr Sallman also serves as lead principal investigator for multiple cellular therapy trials including chimeric antigen receptor cell therapy (CAR-T) and T-cell receptor therapy (TCR).

    Dr Sallman has authored and co-authored numerous articles, books, book chapters and abstracts, and serves as a reviewer for multiple journals. He received a Young Investigator grant from the MDS Foundation in 2017 and was awarded a Career Development grant from the Vera and Joseph Dresner Foundation in 2018.

    Dr David Sallman discloses: Advisory board or panel fees from AvenCell, bluebird bio, Bristol Myers Squibb, Intellia Therapeutics, Jasper Therapeutics, Kite Pharma, Novartis, Servier, Shattuck Labs and Syndax. Consultancy fees from AbbVie, Affimed, Gilead, Molecular Partners AG, Precigen Therapeutics Inc, Takeda and Zentalis Pharmaceuticals. Grants or research support from Aprea and Jazz Pharmaceuticals. Speaker’s bureau fees from Bristol Myers Squibb, Incyte and Servier.
    Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    CORRECT!
    Next question
    touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Haematological Malignancies

    EU PARTNER

    US PARTNER

    An Introduction to Haematological Malignancies

    In recent years, advances in our understanding of the pathological mechanisms underlying haematological malignancies have led to improved outcomes. Several novel drug classes are now emerging, including chimeric antigen receptor (CAR) T-cell therapy, molecular targeted therapies, bispecific T-cell engaging antibodies, CD47 blockade therapy and antibody-drug conjugates. Many challenges remain, however, including how best to combine agents and determining where new therapies fit into the treatment paradigm.

    Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.”

    Our supporting partners do not constitute an endorsement of the content on this page.

    Haematological Malignancies Content

    Haematological Malignancies, Haematology
    Watch Time: 34 mins
    touchTALKS
    What’s on the horizon for higher-risk MDS? An update on emerging novel agents
    CE/CME ACCREDITED Dr David Sallman

    Dr David Sallman reviews advances in HR-MDS management, including the mode of action and latest clinical data for emerging treatments.

    Learning objectives
    Learning Objectives
    • Recall the mechanisms of action for key emerging treatments for patients with HR-MDS
    • Describe the latest efficacy data for key emerging treatments for patients with HR-MDS
    • Discuss the safety profile of key emerging treatments for patients with HR-MDS
    Leukaemia, Haematological Malignancies
    Watch Time: 62 mins
    touchSATELLITE SYMPOSIUM
    Tackling unmet needs in chronic myeloid leukaemia: What’s next in the treatment algorithm?
    Prof. Susanne Saussele, Prof. Massimo Breccia, Prof. Valentín García Gutiérrez Translations available:

    Three experts consider unmet needs in chronic myeloid leukaemia and how new and emerging treatments may help address them.

    Learning objectives
    Learning Objectives
    • Summarize the rationale for new agents in CML in light of treatment safety considerations
    • Discuss the unmet needs for patients with CML in later lines of therapy and how new agents may address these
    • Explain how new and emerging agents may affect the treatment paradigm for patients with CML
    Haematological Malignancies, Leukaemia
    Developed by Touch
    Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
    Watch Time: 3 mins

    The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]

    Haematological Malignancies, Leukaemia
    Developed by Touch
    Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
    Watch Time: 3 mins

    Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]

    Haematological Malignancies, Multiple Myeloma
    Developed by Touch
    Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
    Watch Time: 5 mins

    Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]

    Haematological Malignancies, Multiple Myeloma
    Developed by Touch
    Shaji Kumar, ASH 2022: Highlights in older, frail transplant ineligible patients with multiple myeloma
    Watch Time: 4 mins

    Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma. Abstract 4553: Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (00:25-00:57) Abstract 569: A Dexamethasone Sparing-Regimen […]

    Multiple Myeloma
    Developed by Touch
    Shaji Kumar, ASH 2022: Updated efficacy analysis from the phase III MAIA study in newly-diagnosed multiple myeloma
    Watch Time: 5 mins

    Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the updated efficacy analysis from the phase III MAIA study presented at the recent ASH 2022 congress. There were also some additional post-hoc efficacy analyses on key subgroups (Abstracts 4553 and 3245). Abstract 3245: Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible […]

    Haematological Malignancies, Multiple Myeloma
    Developed by Touch
    Shaji Kumar, ASH 2022: Key clinical trials in smoldering myeloma
    Watch Time: 4 mins

    Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of three key clinical trials presented at ASH 2022 in the field of smoldering myeloma, an area of great interest and opportunity to improve patient overall survival. Abstract 3253: Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety […]

    Haematological Malignancies, Multiple Myeloma
    Developed by Touch
    Shaji Kumar, ASH 2022: Highlights in high-risk newly-diagnosed multiple myeloma
    Watch Time: 3 mins

    Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of high-risk newly-diagnosed multiple myeloma, where it is fundamental to risk stratify patients and develop different treatment strategies. Abstract 752: Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72